ProCE Banner Activity

Unresponsive to PBC Treatment: Second-line and Future PBC Therapies

Clinical Thought

Explore my expert analysis on which patients can benefit from second-line add-on agents and when, along with insights into emerging therapies for effective PBC management.

Released: November 08, 2024

Expiration: November 07, 2025

Share

Faculty

Christopher L. Bowlus

Christopher L. Bowlus, MD

Lena Valente Professor and Chief
Division of Gastroenterology and Hepatology
University of California Davis School of Medicine
Sacramento, California

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Gilead Sciences, Inc.

Faculty Disclosure

Primary Author

Christopher L. Bowlus, MD

Lena Valente Professor and Chief
Division of Gastroenterology and Hepatology
University of California Davis School of Medicine
Sacramento, California

Christopher L. Bowlus, MD: consultant/advisor/speaker: Alynylam, Amgen, ArsenalBio, ChemoMab, Cymabay, Gilead Sciences, GlaxoSmithKline, Intercept, Invea; researcher (paid to institution): Boston Scientific, Calliditas, ChemoMab, COUR, Cymabay, Gilead Sciences, GlaxoSmithKline, Hanmi, Intercept.